Skip to content

De ontwikkeling van een keuzehulp voor patiënten bij de behandeling van diabetes en bijkomende risico's.

Risk management in patients with diabetes mellitus: development and evaluation of a patient-oriented treatment decision aid (PTDA).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27858
Enrollment
450
Registered
2009-08-10
Start date
2010-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Therapy/ Diabetes Mellitus Behandeling Computer-Assisted Decision Making/ Computer-ondersteund Beslissen Patient Education/ Patient Informatie Guideline Adherence/ Richtlijn Adherentie

Interventions

2. Clinical and patient perspective on paper
3. Clinical perspective on computer
4. Clinical and patient perspective on computer. The control group will receive care/information as usual.
The patient-oriented treatment decision aid offers personalized information on possible treatment options and outcomes. The information is intended to empower the patients in taking a proactive role i

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes managed by GPs.

Exclusion criteria

Exclusion criteria: 1. Dementia; 2. Known cognitive deficits; 3. Not able to read Dutch; 4. Terminal illness; 5. Previous stroke or heart disease; 6. Above 65 years of age at diagnosis diabetes.

Design outcomes

Primary

MeasureTime frame
Patient empowerment measured with Diabetes Empowerment Scale (overall and subscale ‘Setting and Achieving Goals’).

Secondary

MeasureTime frame
1. Patient perceptions about benefits and risks of treatment options (BMQ); 2. Negative emotions (PAID); 3. Satisfaction with care (PEQ-D); 4. Medication treatment; 5. Control of risk factors (UKPDS predicted 10-year risks).

Contacts

Public ContactP. Denig

ector F/Department of Clinical Pharmacology, University Medical Center Groningen, PO Box 196,

p.denig@med.umcg.nl+31503633205

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)